Healthcare Mergers, Acquisitions and Other Transactions

The healthcare industry is in the beginning of a transformational stage that will touch every healthcare organization. Traditional ownership structures of healthcare entities will be challenged and new alignments and efficiencies conceived and implemented. We are experienced in this type of transformative transaction - from the initial management and Boardroom discussions to negotiating and closing mergers, acquisitions, joint-ventures and other collaborations. The combination of our senior transactional counsel and our antitrust and regulatory expertise makes us valued counsel in these transactions.

Our attorneys specializing in healthcare industry transactions have deep experience in the unique business, regulatory, reimbursement and risk allocation factors that shape healthcare transactions. Purchasers frequently engage our health industry lawyers for specialized due diligence examinations of target company compliance history relating to anti-kickback, Stark, FDA, reimbursement and other laws. Our practice is national in scope and involves all substantive aspects of healthcare transactions, including multistate regulatory approvals, legal risk assessments, tax structuring and antitrust analysis, and public company and going-private issues.

Recognitions:

• Recognized as a leading law firm in the area of Corporate/M & A by Chambers USA: America’s Leading Lawyers for Business 2007
  
  
• A senior transactional attorney was named one of 12 Outstanding Healthcare Transaction Lawyers by Nightingale’s Healthcare News in 2006

Representative Public Company Transactions:

• AmeriChoice Corporation sale to UnitedHealthGroup Inc. ($560 million)
  
  
• Caremark Rx, Inc. merger with CVS ($26 billion)
  
  
• Caremark Rx, Inc. acquisition of Advance PCS ($5.6 billion)
  
  
• Horizon Medical Products, Inc. merger with RITA Medical Systems, Inc. ($104 million)
  
  
• Per-Se Technologies, Inc. sale to McKesson Corp. ($1.8 billion)
  
  
• Per-Se Technologies, Inc. acquisition of NDC Health Corporation ($1 billion)
  
  
• Serologicals Corporation sale to Millipore Corporation ($1.4 billion)